Meeting
2022 ASCO Genitourinary Cancers Symposium
Effect of androgen receptor directed therapy in prostate cancer patients with COVID-19.
Authors
Serhan Unlu
Yale University, New Haven, CT
Serhan Unlu , Junghee Jenny Shin , Jennefer Par-Young , Joseph Vinetz , Daniel P. Petrylak , Insoo Kang , Joseph W. Kim
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session A: Prostate Cancer
Track
Prostate Cancer - Advanced,Prostate Cancer - Localized
Sub Track
Translational Research, Tumor Biology, Biomarkers, and Pathology
Citation
J Clin Oncol 40, 2022 (suppl 6; abstr 161)
DOI
10.1200/JCO.2022.40.6_suppl.161
Abstract #
161
Poster Bd #
J4
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
Outcomes of active cancer patients with COVID-19 infection treated with COVID-19 neutralizing monoclonal antibodies.
First Author: Justin Shaya
Poster
2021 Genitourinary Cancers Symposium
Severe-COVID-19 and mortality among patients (pts) with prostate cancer (PCa) receiving androgen deprivation therapy (ADT).
First Author: Matthew D Tucker
Poster
2021 Genitourinary Cancers Symposium
The role of androgen deprivation therapy on the clinical course of COVID-19 infection in men with prostate cancer.
First Author: Vaibhav G. Patel
Poster
2024 ASCO Breakthrough
Mortality and economic cost in common primary cancer admitted with COVID-19: Analysis of NIS 2020.
First Author: Thanathip Suenghataiphorn